AmycretinvsNN1706

Amycretin is a unimolecular co-agonist that simultaneously activates both the GLP-1 receptor and the amylin (AMY) receptor — the first peptide engineered to combine these two complementary satiety pathways in a single molecule rather than as a two-drug combination. The design philosophy is to deliver the additive weight-loss benefit demonstrated by CagriSema (semaglutide + cagrilintide) without the manufacturing, dosing, and patient-acceptance complexities of co-formulating two separate drugs.

The GLP-1 component drives appetite suppression centrally through hypothalamic POMC/CART activation and NPY/AgRP inhibition, slows gastric emptying via vagal signalling, and stimulates glucose-dependent insulin secretion from pancreatic beta cells. The amylin component activates calcitonin-receptor/RAMP heterodimer complexes concentrated in the area postrema and nucleus tractus solitarius — brainstem regions outside the blood-brain barrier that form a parallel satiety circuit reducing meal size and food-seeking behaviour through neuroanatomically distinct pathways.

Because GLP-1 and amylin signal through different receptor families and target different neurons in the appetite control network, their effects are additive rather than redundant. Phase 1b/2a data showed up to 22% body weight reduction at 36 weeks for the subcutaneous form — comparable to CagriSema with a simpler one-molecule profile. A particularly notable feature is the parallel development of an oral formulation, which would be the first oral peptide combination therapy for obesity if approved. Novo Nordisk's branded development name is zenagamtide, and the molecule is positioned as the company's strategic answer to retatrutide and tirzepatide.

NN1706 is a once-daily GLP-1/GIP/glucagon triple receptor agonist — Novo Nordisk's mechanistic equivalent to Eli Lilly's retatrutide, designed to activate all three pathways simultaneously in a single molecule. Each receptor contributes complementary metabolic effects: GLP-1 agonism centrally suppresses appetite, slows gastric emptying, and stimulates glucose-dependent insulin secretion; GIP agonism augments insulin response and modulates adipose lipid handling; and glucagon receptor agonism in the liver drives fatty acid oxidation, ketogenesis, and hepatic glucose output, while in brown and beige adipose tissue it promotes thermogenesis and increases whole-body energy expenditure.

The key engineering challenge in any glucagon-containing multi-agonist is balancing glucagon's hyperglycemic tendency against the glucose-lowering effect of GLP-1 and GIP. NN1706's receptor potency ratios are tuned so that incretin-driven insulinotropic effects sufficiently offset glucagon-driven glucose production, producing net glycemic improvement alongside enhanced fat oxidation. The glucagon component is what differentiates triple agonists like NN1706 and retatrutide from dual GLP-1/GIP agonists like tirzepatide — the additional energy-expenditure and hepatic-fat-mobilising effects of glucagon are the main reason triple agonists have produced higher weight-loss numbers in early trials.

The pharmacokinetic profile gives NN1706 a half-life of roughly 14-18 hours, matched to once-daily subcutaneous dosing rather than the once-weekly schedule of retatrutide. The trade-off is more injections per week against tighter dose control, smoother plasma concentrations, and faster ability to adjust or pause dosing if side effects emerge. The first human data published in 2026 from Phase 1 trials in rodents, monkeys, and humans showed meaningful weight loss with an acceptable initial tolerability profile, setting up Phase 2 obesity and type 2 diabetes trials.